Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.45 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783205 | 0.89 | HTR6 (0.42) | HTR6L3MBTL1CCR1TSHRHTT | |
| SCHEMBL5785250 | 0.88 | HTR6 (0.38) | HTR6CNR2CYP2C9L3MBTL1EPHX2 | |
| SCHEMBL5421797 | 0.86 | MEN1 (0.44) | HTR6L3MBTL1CCR1TSHRMAPK1 | |
| SCHEMBL5785930 | 0.85 | PKM (0.41) | HTR6CCR1TSHRMAPK1RXFP1 | |
| SCHEMBL5426366 | 0.84 | HTR6 (0.47) | HTR6CCR1RXFP1ALDH1A1LMNA | |
| SCHEMBL5426070 | 0.83 | CCR1 (0.47) | HTR6EPHX2CNR1CCR1KMT2A | |
| SCHEMBL3144504 | 0.82 | HTR6 (0.65) | HTR6 | |
| SCHEMBL5787382 | 0.81 | TSHR (0.43) | HTR6L3MBTL1CCR1TSHRMAPK1 | |
| SCHEMBL5432653 | 0.81 | TSHR (0.54) | L3MBTL1TSHRMAPK1HTTKMT2A | |
| SCHEMBL5426197 | 0.81 | EPHX2 (0.46) | HTR6CYP2C9EPHX2CCR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | claimed |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | HTR6, HTR5A, P2RX6 | HTR6 1/4885CNR2 58/4885CYP2C9 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.